Colorectal carcinogensis and suppression of tumor development by inhibition of enzymes and molecular targets

Current Enzyme Inhibition

Volumn 5, Issue 1, 2009, Pages 1-26

  Yasui, Yumiko ^a   Mihe, Kim ^a   Oyama, Takeru ^a   Tanaka, Takuji ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA CATENIN ANTAGONIST; BIOLOGICAL MARKER; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DNA; EFLORNITHINE; ESTROGEN RECEPTOR BETA INHIBITOR; HEME OXYGENASE 1 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOXYGENASE INHIBITOR; MICRORNA; NONSTEROID ANTIINFLAMMATORY AGENT; ORNITHINE DECARBOXYLASE INHIBITOR; PIWI INTERACTING RNA; POLYAMINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; RETINOID X RECEPTOR ALPHA INHIBITOR; SMALL INTERFERING RNA; STAT3 PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER INHIBITION; CANCER PREVENTION; CARDIOTOXICITY; CLINICAL TRIAL; COLON CARCINOGENESIS; COLORECTAL CANCER; DISEASE MARKER; DNA DAMAGE; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; NEPHROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ANIMALIA;

EID: 63149135635     PISSN: 15734080     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340809787314247     Document Type: Review

References (264)

1. O'Shaughnessy, J.A.; Kelloff, G.J.; Gordon, G.B.; Dannenberg, A.J.; Hong, W.K.; Fabian, C.J.; Sigman, C.C.; Bertagnolli, M.M.; Stratton, S.P.; Lam, S.; Nelson, W.G.; Meyskens, F.L.; Alberts, D.S.; Follen, M.; Rustgi, A.K.; Papadimitrakopoulou, V.; Scardino, P.T.; Gazdar, A.F.; Wattenberg, L.W.; Sporn, M.B.; Sakr, W.A.; Lippman, S.M.; Von Hoff, D.D.T. Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development. Clin. Cancer Res., 2002, 8, 314-46.
2. Tomaru, Y.; Hayashizaki, Y. Cancer research with non-coding RNA. Cancer Sci., 2006, 97, 1285-90.
3. Ebert, M.P.; Schmid, R.; Röcken, C. Need for a paradigm shift in cancer prevention and clinical oncology. Expert Rev. Anticancer Ther., 2007, 7, 1363-7.
4. Freedman, L. Quantitative science methods for biomarker validation in chemoprevention trials. Cancer Biomark., 2007, 3, 135-40.
5. Gao, J.X. Cancer stem cells: The lessons from pre-cancerous stem cells. J. Cell Mol. Med., 2008, 12, 67-96.
6. Kim, Y.S.; Maruvada, P.; Milner, J.A. Metabolomics in biomarker discovery: Future uses for cancer prevention. Future Oncol., 2008, 4, 93-102.
7. Kingsley, B.S.; Schmeichel, K.L.; Rubin, C.H. An update on cancer cluster activities at the Centers for Disease Control and Prevention. Environ. Health Perspect., 2007, 115, 165-71.
8. Taylor, E.L.; Gant, T.W. Emerging fundamental roles for non-coding RNA species in toxicology. Toxicology, 2008, 246, 34-9.
9. Pretlow, T.P.; O'Riordan, M.A.; Pretlow, T.G.; Stellato, T.A. Aberrant crypts in human colonic mucosa: Putative preneoplastic lesions. J. Cell Biochem., 1992, 16G (Suppl.), 55-62.
10. Takayama, T.; Katsuki, S.; Takahashi, Y.; Ohi, M.; Nojiri, S.; Sakamaki, S.; Kato, J.; Kogawa, K.; Miyake, H.; Niitsu, Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N. Engl. J. Med., 1998, 339, 1277-84.
11. Mori, H.; Hata, K.; Yamada, Y.; Kuno, T.; Hara, A. Significance and role of early-lesions in experimental colorectal carcinogenesis. Chem. Biol. Interact., 2005, 155, 1-9.
12. Wallace, H.M.; Fraser, A.V.; Hughes, A. A perspective of polyamine metabolism. Biochem. J., 2003, 376, 1-14.
13. Huang, Y.; Pledgie, A.; Casero, R.A.J.; Davidson, N.E. Molecular mechanisms of polyamine analogs in cancer cells. Anticancer Drugs, 2005, 16, 229-41.
14. Seiler, N. Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect. Part 1. Selective enzyme inhibitors. Curr. Drug Targets, 2003, 4, 537-64.
15. Pegg, A.E.; Shantz, L.M.; Coleman, C.S. Ornithine decarboxylase as a target for chemoprevention. J. Cell Biochem., 1995, 22 (Suppl.), 132-8.
16. Casero, R.A.J.; Frydman, B.; Stewart, T.M.; Woster, P.M. Significance of targeting polyamine metabolism as an antineoplastic strategy: Unique targets for polyamine analogues. Proc. West Pharmacol. Soc., 2005, 48, 24-30.
17. Jänne, J.; Pösö, H.; Raina, A. Polyamines in rapid growth and cancer. Biochim. Biophys. Acta, 1978, 473, 241-93.
18. Wallace, H.M.; Caslake, R. Polyamines and colon cancer. Eur. J. Gastroenterol. Hepatol., 2001, 13, 1033-9.
19. Wallace, H.M.; Niiranen, K. Polyamine analogues - an update. Amino Acids, 2007, 33, 1033-9.
20. Bachrach, U. Polyamines and cancer: Minireview article. Amino Acids, 2004, 26, 307-9.
21. Milovic, V.; Turchanowa, L. Polyamines and colon cancer. Biochem. Soc. Trans., 2003, 31, 381-3.
22. Gerner, E.W.; Meyskens, F.L.J.; Goldschmid, S.; Lance, P.; Pelot, D. Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention. Amino Acids, 2007, 33, 189-95.
23. Keren-Paz, A.; Bercovich, Z.; Kahana, C. Antizyme inhibitor: A defective ornithine decarboxylase or a physiological regulator of polyamine biosynthesis and cellular proliferation. Biochem. Soc. Transact., 2007, 35, 311-13.
24. Prescott, S.M.; Fitzpatrick, F.A. Cyclooxygenase-2 and carcinogenesis. Biochim. Biophys. Acta, 2000; 1470, M69-78.
25. Herschman, H.R. Prostaglandin synthase 2. Biochim. Biophys. Acta, 1996, 1299, 125-40.
26. Spencer, A.G.; Thuresson, E.; Otto, J.C.; Song, I.; Smith, T.; DeWitt, D.L.;. Garavito, R.M.; Smith, W.L. The membrane binding domains of prostaglandin endoperoxide H synthases 1 and 2. Peptide mapping and mutational analysis. J. Biol. Chem., 1999, 274, 32936-42.
27. Williams, C.S.; Mann, M.; DuBois, R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene, 1999, 18, 7908-16.
28. Eberhart, C.E.; Coffey, R.J.; Radhika, A.; Giardiello, F.M.; Ferrenbach, S.; DuBois, R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 1994, 107, 1183-8.
29. O'Neill, G.P.; Ford-Hutchinson, A.W. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett., 1993, 330, 156-60.
30. Rigas, B.; Goldman, I.S.; Levine, L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med., 1993, 122, 518-23.
31. Sano, H.; Kawahito, Y.; Wilder, R.; Hashiramoto, A.; Mukai, S.; Asai, K.; Kimura, S.; Kato, H.; Kondo, M.; Hla, T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res., 1995, 55, 3785-9.
32. Telliez, A.; Furman, C.; Pommery, N.; Hénichart, J.P. Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: Topical therapeutic strategies targeting COX-2 expression and activity. Anticancer Agents Med. Chem., 2006, 6, 187-208.
33. DuBois, R.N.; Radhika, A.; Reddy, B.S.; Entingh, A.J. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology, 1996, 110, 1259-62.
34. Kutchera, W.; Jones, D.A.; Matsunami, N.; Groden, J.; McIntyre, T.M.; Zimmerman, G.A.; White, R.L.; Prescott, S.M. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect. Proc. Natl. Acad. Sci. USA, 1996, 93, 4816-20.
35. Tsujii, M.; Kawano, S.; Tsuji, S.; Sawaoka, H.; Hori, M.; DuBois, R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 1998, 93, 705-16.
36. Chan, A.T.; Ogino, S.; Fuchs, C.S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med., 2007, 356, 2131-42.
37. DuBois, R.N.; Smalley, W.E. Cyclooxygenase, NSAIDs, and colorectal cancer. J. Gastroenterol., 1996, 31, 898-906.
38. Sheng, H.; Shao, J.; Kirkland, S.C.; Isakson, P.; Coffey, R.J.; Morrow, J.; Beauchamp, R.D.; DuBois, R.N. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest., 1997; 99, 2254-9.
39. Rayyan, Y.; Williams, J.; Rigas, B. The role of NSAIDs in the prevention of colon cancer. Cancer Invest., 2002, 20, 1002-11.
40. Dubé, C.; Rostom, A.; Lewin, G.; Tsertsvadze, A.; Barrowman, N.; Code, C.; Sampson, M.; Moher, D. The use of aspirin for primary prevention of colorectal cancer: A systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern. Med., 2007, 146, 365-75.
41. Gupta, R.A.; Dubois, R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer, 2001, 1, 11-21.
42. Bresalier, R.S.; Sandler, R.S.; Quan, H.; Bolognese, J.A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M.A.; Baron, J.A. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med., 2005, 352, 1092-102.
43. Rostom, A.; Dubé, C.; Lewin, G.; Tsertsvadze, A.; Barrowman, N.; Code, C.; Sampson, M.; Moher, D.; Force., U.S.P.S.T. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: A systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern. Med., 2007, 146, 376-89.
44. Swamy, M.V.; Cooma, I.; Patlolla, J.M.; Simi, B.; Reddy, B.S.; Rao, C.V. Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: Novel strategies for colon cancer prevention and treatment. Mol. Cancer Ther., 2004, 3, 215-21.
45. DuBois, R.N. New paradigms for cancer prevention. Carcinogenesis, 2001, 22, 691-2.
46. Kashfi, K.; Ryan, Y.; Qiao, L.L.; Williams, J.L.; Chen, J.; Del Soldato, P.; Traganos, F.; Rigas, B. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: Evidence of a tissue type-independent effect. J. Pharmacol. Exp. Ther., 2002, 303, 1273-82.
47. Rigas, B.; Kashfi, K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol. Med., 2004, 10, 324-30.
48. Yeh, R.K.; Chen, J.; Williams, J.L.; Baluch, M.; Hundley, T.R.; Rosenbaum, R.E.; Kalala, S.; Traganos, F.; Benardini, F.; del Soldato, P.; Kashfi, K.; Rigas, B. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: A general pharmacological property? Biochem. Pharmacol., 2004, 67, 2197-205.
49. Rao, C.V.; Reddy, B.S.; Steele, V.E.; Wang, C.X.; Liu, X.; Ouyang, N.; Patlolla, J.M.; Simi, B.; Kopelovich, L.; Rigas, B. Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: Effects on molecular targets. Mol. Cancer Ther., 2006, 5, 1530-8.
50. Fries, S.; Grosser, T.; Price, T.S.; Lawson, J.A.; Kapoor, S.; De-Marco, S.; Pletcher, M.; Wiltshire, T.; FitzGerald, G.A. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology, 2006, 130, 55-64.
51. Ding, X.Z.; Hennig, R.; Adrian, T.E. Lipoxygenase and cyclooxygenase metabolism: New insights in treatment and chemoprevention of pancreatic cancer. Mol. Cancer, 2003, 2, 10.
52. Ghosh, J.; Myers, C.E. Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells. Adv. Exp. Med. Biol., 1999, 469, 577-82.
53. Gunning, W.T.; Kramer, P.M.; Steele, V.E.; Pereira, M.A. Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res., 2002, 62, 4199-201.
54. Steele, V.E.; Holmes, C.A.; Hawk, E.T.; Kopelovich, L.; Lubet, R.A.; Crowell, J.A.; Sigman, C.C.; Kelloff, G.J. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomarkers Prev., 1999, 8, 467-83.
55. Nie, D.; Che, M.; Grignon, D.; Tang, K.; Honn, K.V. Role of eicosanoids in prostate cancer progression. Cancer Metastasis Rev., 2001, 20, 195-206.
56. Tang, D.G.; Honn, K.V. Apoptosis of W256 carcinosarcoma cells of the monocytoid origin induced by NDGA involves lipid peroxidation and depletion of GSH: Role of 12-lipoxygenase in regulating tumor cell survival. J. Cell Physiol., 1997, 172, 155-70.
57. Shureiqi, I.; Chen, D.; Lotan, R.; Yang, P.; Newman, R.A.; Fischer, S.M.; Lippman, S.M. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res., 2000, 60, 6846-50.
58. Borgeat, P.; Hamberg, M.; Samuelsson, B. Transformation of arachidonic acid and homo-gamma-linolenic acid by rabbit polymorphonuclear leukocytes. Monohydroxy acids from novel lipoxygenases. J. Biol. Chem., 1976, 251, 7816-20.
59. Ye, Y.N.; Wu, W.K.; Shin, V.Y.; Cho, C.H. A mechanistic study of colon cancer growth promoted by cigarette smoke extract. Eur. J. Pharmacol., 2005, 519, 52-7.
60. Barresi, V.; Grosso, M.; Vitarelli, E.; Tuccari, G.; Barresi, G. 5-Lipoxygenase is coexpressed with Cox-2 in sporadic colorectal cancer: a correlation with advanced stage. Dis. Colon Rectum, 2007, 50, 1576-84.
61. Soumaoro, L.T.; Iida, S.; Uetake, H.; Ishiguro, M.; Takagi, Y.; Higuchi, T.; Yasuno, M.; Enomoto, M.; Sugihara, K. Expression of 5-lipoxygenase in human colorectal cancer. World J. Gastroenterol., 2006, 12, 6355-60.
62. Ohd, J.F.; Wikström, K.; Sjölander, A. Leukotrienes induce cell-survival signaling in intestinal epithelial cells. Gastroenterology, 2000, 119, 1007-18.
63. Sjöström, M.; Jakobsson, P.J.; Juremalm, M.; Ahmed, A.; Nilsson, G.; Macchia, L.; Haeggström, J.Z. Human mast cells express two leukotriene C(4) synthase isoenzymes and the CysLT(1) receptor. Biochim. Biophys. Acta, 2002, 1583, 53-62.
64. Chen, X.; Wang, S.; Wu, N.; Sood, S.; Wang, P.; Jin, Z.; Beer, D.G.; Giordano, T.J.; Lin, Y.; Shih, W.C.; Lubet, R.A.; Yang, C.S. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and nhibitory effects of zileuton and celecoxib on carcinogenesis. Clin. Cancer Res., 2004, 10, 6703-9.
65. Hennig, R.; Grippo, P.; Ding, X.Z.; Rao, S.M.; Buchler, M.W.; Friess, H.; Talamonti, M.S.; Bell, R.; Adrian, T.E. 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res., 2005, 65, 6011-6.
66. Gronert, K.; Martinsson-Niskanen, T.; Ravasi, S.; Chiang, N.; Serhan, C.N. Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. Am. J. Pathol., 2001, 158, 3-9.
67. Grosser, T.; Fries, S.; FitzGerald, G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J. Clin. Invest., 2006, 116, 4-15.
68. Goossens, L.; Pommery, N.; Hénichart, J.P. COX-2/5-LOX dual acting anti-inflammatory drugs in cancer chemotherapy. Curr. Top. Med. Chem., 2007, 7, 283-96.
69. Leval, X.; Julemont, F.; Delarge, J.; Pirotte, B.; Dogne, J.M. New trends in dual 5-LOX/COX inhibition. Curr. Med. Chem., 2002, 9, 941-62.
70. Horizoe, T.; Nagakura, N.; Chiba, K.; Shirota, H.; Shinoda, M.; Kobayashi, N.; Numata, H.; Okamoto, Y.; Kobayashi, S. ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model. Inflamm. Res., 1998, 47, 375-83.
71. Martel-Pelletier, J.; Lajeunesse, D.; Reboul, P.; Pelletier, J.P. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum. Dis., 2003, 62, 501-9.
72. Kirchner, T.; Aparicio, B.; Argentieri, D.C.; Lau, C.Y.; Ritchie, D.M. Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins. Leukot. Essent. Fatty Acids, 1997, 56, 417-23.
73. Alvaro-Gracia, J.M. Licofelone - clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology (Oxford), 2004, 43 (Suppl. 1), i21-5.
74. Kulkarni, S.K.; Singh, V.P. Licofelone - a novel analgesic and anti-inflammatory agent. Curr. Top. Med. Chem., 2007, 7, 251-63.
75. Jenkins, D.C.; Charles, I.G.; Thomsen, L.L.; Moss, D.W.; Holmes, L.S.; Baylis, S.A.; Rhodes, P.; Westmore, K.; Emson, P.C.; Moncada, S. Roles of nitric oxide in tumor growth. Proc. Natl. Acad. Sci. USA, 1995, 92, 4392-6.
76. Mollace, V.; Muscoli, C.; Masini, E.; Cuzzocrea, S.; Salvemini, D. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol. Rev., 2005, 57, 217-52.
77. Cui, S.; Reichner, J.S.; Mateo, R.B.; Albina, J.E. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. Cancer Res., 1994, 54, 2462-7.
78. Salvemini, D.; Misko, T.P.; Masferrer, J.L.; Seibert, K.; Currie, M.G.; Needleman, P. Nitric oxide activates cyclooxygenase enzymes. Proc. Natl. Acad. Sci. USA, 1993, 90, 7240-4.
79. Salvemini, D.; Settle, S.L.; Masferrer, J.L.; Seibert, K.; Currie, M.G.; Needleman, P. Regulation of prostaglandin production by nitric oxide; an in vivo analysis. Br. J. Pharmacol., 1995, 114, 1171-8.
80. Xiong, Q.; Shi, Q.; Le, X.; Wang, B.; Xie, K. Regulation of interleukin-8 expression by nitric oxide in human pancreatic adenocarcinoma. J. Interferon. Cytokine Res., 2001, 21, 529-37.
81. Morris, S.M.J.; Billiar, T.R. New insights into the regulation of inducible nitric oxide synthesis. Am. J. Physiol. Cell Physiol., 1994, 266, E829-39.
82. Xie, K.; Huang, S.; Dong, Z.; Juang, S.H.; Wang, Y.; Fidler, I.J. Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene. J. Natl. Cancer Inst., 1997, 89, 421-7.
83. Gansauge, S.; Nussler, A.K.; Beger, H.G.; Gansauge, F. Nitric oxide-induced apoptosis in human pancreatic carcinoma cell lines is associated with a G1-arrest and an increase of the cyclin-dependent kinase inhibitor p21WAF1/CIP1. Cell Growth Differ., 1998, 9, 611-7.
84. Wang, B.; Wei, D.; Crum, V.E.; Richardson, E.L.; Xiong, H.H.; Luo, Y.; Huang, S.; Abbruzzese, J.L.; Xie, K. A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis. Oncogene, 2003, 22, 1771-82.
85. Bogdan, C. Nitric oxide and the immune response. Nat. Immunol., 2001, 2, 907-16.
86. Lala, P.K.; Chakraborty, C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol., 2001, 2, 149-56.
87. Wink, D.A.; Vodovotz, Y.; Cook, J.A.; Krishna, M.C.; Kim, S.; Coffin, D.; DeGraff, W.; Deluca, A.M.; Liebmann, J.; Mitchell, J.B. The role of nitric oxide chemistry in cancer treatment. Biochemistry (Mosc), 1998, 63, 802-9.
88. Ambs, S.; Bennett, W.P.; Merriam, W.G.; Ogunfusika, M.O.; Oser, S.M.; Harrington, A.M.; Shields, P.G.; Felley-Bosco, E.; Hussain, S.P.; Harris, C.C. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J. Natl. Cancer Inst., 1999, 91, 86-8.
89. Ambs, S.; Merriam, W.G.; Bennett, W.P.; Felley-Bosco, E.; Ogunfusika, M.O.; Oser, S.M.; Klein, S.; Shields, P.G.; Billiar, T.R.; Harris, C.C. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res., 1998, 58, 334-41.
90. Chhatwal, V.J.; Ngoi, S.S.; Chan, S.T.; Chia, Y.W.; Moochhala, S.M. Aberrant expression of nitric oxide synthase in human polyps, neoplastic colonic mucosa and surrounding peritumoral normal mucosa. Carcinogenesis, 1994, 15, 2081-5.
91. Moochhala, S.; Chhatwal, V.J.; Chan, S.T.; Ngoi, S.S.; Chia, Y.W.; Rauff, A. Nitric oxide synthase activity and expression in human colorectal cancer. Carcinogenesis, 1996, 17, 1171-4.
92. Crowell, J.A.; Steele, V.E.; Sigman, C.C.; Fay, J.R. Is inducible nitric oxide synthase a target for chemoprevention? Mol. Cancer Ther., 2003, 2, 815-23.
93. Hofseth, L.J.; Hussain, S.P.; Wogan, G.N.; Harris, C.C. Nitric oxide in cancer and chemoprevention. Free Radic. Biol. Med., 2003, 34, 955-68.
94. Ahn, B.; Ohshima, H. Suppression of intestinal polyposis in Apc(Min/+) mice by inhibiting nitric oxide production. Cancer Res., 2001, 61, 8357-60.
95. Nam, K.T.; Oh, S.Y.; Ahn, B.; Kim, Y.B.; Jang, D.D.; Yang, K.H.; Hahm, K.B.; Kim, D.Y. Decreased Helicobacter pylori associated gastric carcinogenesis in mice lacking inducible nitric oxide synthase. Gut, 2004, 53, 1250-5.
96. Rao, C.V.; Indranie, C.; Simi, B.; Manning, P.T.; Connor, J.R.; Reddy, B.S. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res., 2002, 62, 165-70.
97. Kohno, H.; Suzuki, R.; Curini, M.; Epifano, F.; Maltese, F.; Gonzales, S.P.; Tanaka, T. Dietary administration with prenyloxycoumarins, auraptene and collinin, inhibits colitis-related colon carcinogenesis in mice. Int. J. Cancer, 2006, 118, 2936-42.
98. Kohno, H.; Takahashi, M.; Yasui, Y.; Suzuki, R.; Miyamoto, S.; Kamanaka, Y.; Naka, M.; Maruyama, T.; Wakabayashi, K.; Tanaka, T. A specific inducible nitric oxide synthase inhibitor, ONO-1714 attenuates inflammation-related large bowel carcinogenesis in male Apc (Min/+) mice. Int. J. Cancer, 2007, 121, 506-13.
99. Tanaka, T.; Kohno, H.; Shimada, R.; Kagami, S.; Yamaguchi, F.; Kataoka, S.; Ariga, T.; Murakami, A.; Koshimizu, K.; Ohigashi, H. Prevention of colonic aberrant crypt foci by dietary feeding of garcinol in male F344 rats. Carcinogenesis, 2000, 21, 1183-9.
100. Tanaka, T.; Kohno, H.; Suzuki, R.; Yamada, Y.; Sugie, S.; Mori, H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci., 2003, 94, 965-73.
101. Suzuki, R.; Kohno, H.; Sugie, S.; Nakagama, H.; Tanaka, T. Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. Carcinogenesis, 2006, 27, 162-9.
102. Suzuki, R.; Kohno, H.; Sugie, S.; Tanaka, T. Sequential observations on the occurrence of preneoplastic and neoplastic lesions in mouse colon treated with azoxymethane and dextran sodium sulfate. Cancer Sci., 2004, 95, 721-7.
103. Suzuki, R.; Kohno, H.; Sugie, S.; Tanaka, T. Dose-dependent promoting effect of dextran sodium sulfate on mouse colon carcinogenesis initiated with azoxymethane. Histol. Histopathol., 2005, 20, 483-92.
104. Suzuki, R.; Miyamoto, S.; Yasui, Y.; Sugie, S.; Tanaka, T. Global gene expression analysis of the mouse colonic mucosa treated with azoxymethane and dextran sodium sulfate. BMC Cancer, 2007, 7, 84.
105. Tanaka, T.; Kohno, H.; Suzuki, R.; Hata, K.; Sugie, S.; Niho, N.; Sakano, K.; Takahashi, M.; Wakabayashi, K. Dextran sodium sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+) mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int. J. Cancer, 2006, 118, 25-34.
106. Tanaka, T.; Suzuki, R.; Kohno, H.; Sugie, S.; Takahashi, M.; Wakabayashi, K. Colonic adenocarcinomas rapidly induced by the combined treatment with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate in male ICR mice possess beta-catenin gene mutations and increases immunoreactivity for beta-catenin, cyclooxygenase-2 and inducible nitric oxide synthase. Carcinogenesis, 2005, 26, 229-38.
107. Thomsen, L.L.; Scott, J.M.; Topley, P.; Knowles, R.G.; Keerie, A.J.; Frend, A.J. Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: Studies with 1400W, a novel inhibitor. Cancer Res., 1997, 57, 3300-4.
108. Xu, W.; Liu, L.Z.; Loizidou, M.; Ahmed, M.; Charles, I.G. The role of nitric oxide in cancer. Cell Res., 2002, 12, 311-20.
109. Hussain, S.P.; Trivers, G.E.; Hofseth, L.J.; He, P.; Shaikh, I.; Mechanic, L.E.; Doja, S.; Jiang, W.; Subleski, J.; Shorts, L.; Haines, D.; Laubach, V.E.; Wiltrout, R.H.; Djurickovic, D.; Harris, C.C. Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Res., 2004, 64, 6849-53.
110. Scott, D.J.; Hull, M.A.; Cartwright, E.J.; Lam, W.K.; Tisbury, A.; Poulsom, R.; Markham, A.F.; Bonifer, C.; Coletta, P.L. Lack of inducible nitric oxide synthase promotes intestinal tumorigenesis in the Apc(Min/ +) mouse. Gastroenterology, 2001, 121, 889-99.
111. Kim, S.F.; Huri, D.A.; Snyder, S.H. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science, 2005, 310, 1966-70.
112. Tozer, G.M.; Prise, V.E.; Wilson, J.; Cemazar, M.; Shan, S.; Dewhirst, M.W.; Barber, P.R.; Vojnovic, B.; Chaplin, D.J. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res., 2001, 61, 6413-22.
113. Niu, J.; Li, Z.; Peng, B.; Chiao, P.J. Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells. J. Biol. Chem., 2004, 279, 16452-62.
114. Baldwin, A.S.J. The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu Rev. Immunol., 1996, 14, 649-83.
115. Kashfi, K.; Borgo, S.; Williams, J.L.; Chen, J.; Gao, J.; Glekas, A.; Benedini, F.; Del Soldato, P.; Rigas, B. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J. Pharmacol. Exp. Ther., 2005, 312, 978-88.
116. Yamamoto, Y.; Gaynor, R.B. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J. Clin. Invest., 2001, 107, 135-42.
117. Shi, Q.; Le, X.; Abbruzzese, J.L.; Wang, B.; Mujaida, N.; Matsushima, K.; Huang, S.; Xiong, Q.; Xie, K. Cooperation between transcription factor AP-1 and NF-kappaB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia. J. Interferon Cytokine Res., 1999, 19, 1363-71.
118. Schmid, R.M.; Adler, G. NF-kappaB/rel/IkappaB: Implications in gastrointestinal diseases. Gastroenterology, 2000, 118, 1208-28.
119. Kornmann, M.; Ishiwata, T.; Itakura, J.; Tangvoranuntakul, P.; Beger, H.G.; Korc, M. Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival. Oncology, 1998, 55, 363-9.
120. Shi, Q.; Le, X.; Wang, B.; Xiong, Q.; Abbruzzese, J.L.; Xie, K. Regulation of interleukin-8 expression by cellular pH in human pancreatic adenocarcinoma cells. J. Interferon Cytokine Res., 2000, 20, 1023-8.
121. Xiong, H.Q.; Abbruzzese, J.L.; Lin, E.; Wang, L.; Zheng, L.; Xie, K. NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int. J. Cancer, 2004, 108, 181-8.
122. Brew, R.; Erikson, J.S.; West, D.C.; Kinsella, A.R.; Slavin, J.; Christmas, S.E. Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine, 2000, 12, 78-85.
123. Takeda, A.; Stoeltzing, O.; Ahmad, S.A.; Reinmuth, N.; Liu, W.; Parikh, A.; Fan, F.; Akagi, M.; Ellis, L.M. Role of angiogenesis in the development and growth of liver metastasis. Ann. Surg. Oncol., 2002, 9, 610-6.
124. Arlt, A.; Gehrz, A.; Müerköster, S.; Vorndamm, J.; Kruse, M.L.; Fölsch, U.R.; Schäfer, H. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene, 2003, 22, 3243-51.
125. Fahy, B.N.; Schlieman, M.G.; Virudachalam, S.; Bold, R.J. Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. J. Am. Coll. Surg., 2004, 198, 591-9.
126. Arlt, A.; Vorndamm, J.; Breitenbroich, M.; Fölsch, U.R.; Kalthoff, H.; Schmidt, W.E.; Schäfer, H. Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene, 2001, 2,:859-68.
127. Fujioka, S.; Sclabas, G.M.; Schmidt, C.; Niu, J.; Frederick, W.A.; Dong, Q.G.; Abbruzzese, J.L.; Evans, D.B.; Baker, C.; Chiao, P.J. Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. Oncogene, 2003, 22, 1365-70.
128. Thomas, R.P.; Farrow, B.J.; Kim, S.; May, M.J.; Hellmich, M.R.; Evers, B.M. Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death. Surgery, 2002, 132, 127-34.
129. Nagasaki, K.; Schem, C.; von Kaisenberg, C.; Biallek, M.; Rösel, F.; Jonat, W.; Maass, N. Leucine-zipper protein, LDOC1, inhibits NF-kappaB activation and sensitizes pancreatic cancer cells to apoptosis. Int. J. Cancer, 2003, 105, 454-8.
130. Blanchard, J.A.n.; Barve, S.; Joshi-Barve, S.; Talwalker, R.; Gates, L.K.J. Antioxidants inhibit cytokine production and suppress NF-kappaB activation in CAPAN-1 and CAPAN-2 cell lines. Dig. Dis. Sci., 2001, 46, 2768-72.
131. Mouria, M.; Gukovskaya, A.S.; Jung, Y.; Buechler, P.; Hines, O.J.; Reber, H.A.; Pandol, S.J. Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int. J. Cancer, 2002, 98, 761-9.
132. Plummer, S.M.; Holloway, K.A.; Manson, M.M.; Munks, R.J.; Kaptein, A.; Farrow, S.; Howells, L. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene, 1999, 18, 6013-20.
133. Li Volti, G.; Sacerdoti, D.; Sangras, B.; Vanella, A.; Mezentsev, A.; Scapagnini, G.; Falck, J.R.; Abraham, N.G. Carbon monoxide signaling in promoting angiogenesis in human microvessel endothelial cells. Antioxid. Redox Signal, 2005, 7, 704-10.
134. Sunamura, M.; Duda, D.G.; Ghattas, M.H.; Lozonschi, L.; Motoi, F.; Yamauchi, J.; Matsuno, S.; Shibahara, S.; Abraham, N.G. Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis, 2003, 6, 15-24.
135. Khor, T.O.; Huang, M.T.; Kwon, K.H.; Chan, J.Y.; Reddy, B.S.; Kong, A.N. Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res., 2006, 66, 11580-4.
136. Kweon, M.H.; Adhami, V.M.; Lee, J.S.; Mukhtar, H. Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. J. Biol. Chem., 2006, 281, 33761-72.
137. Xu, C.; Yuan, X.; Pan, Z.; Shen, G.; Kim, J.H.; Yu, S.; Khor, T.O.; Li, W.; Ma, J.; Kong, A.N. Mechanism of action of isothiocyanates: The induction of ARE-regulated genes is associated with activation of ERK and JNK and the phosphorylation and nuclear translocation of Nrf2. Mol. Cancer Ther., 2006, 5, 1918-26.
138. Was, H.; Cichon, T.; Smolarczyk, R.; Rudnicka, D.; Stopa, M.; Chevalier, C.; Leger, J.J.; Lackowska, B.; Grochot, A.; Bojkowska, K.; Ratajska, A.; Kieda, C.; Szala, S.; Dulak, J.; Jozkowicz, A. Overexpression of heme oxygenase-1 in murine melanoma: Increased proliferation and viability of tumor cells, decreased survival of mice. Am. J. Pathol., 2006, 169, 2181-98.
139. Fang, J.; Akaike, T.; Maeda, H. Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment. Apoptosis, 2004, 9, 27-35.
140. Tanaka, S.; Akaike, T.; Fang, J.; Beppu, T.; Ogawa, M.; Tamura, F.; Miyamoto, Y.; Maeda, H. Antiapoptotic effect of haem oxygenase-1 induced by nitric oxide in experimental solid tumour. Br. J. Cancer, 2003, 88, 902-9.
141. Malaguarnera, L.; Quan, S.; Pilastro, M.R.; Abraham, N.G.; Kappas, A. Diminished heme oxygenase potentiates cell death: pyrrolidinedithiocarbamate mediates oxidative stress. Exp. Biol. Med. (Maywood), 2003, 228, 459-65.
142. Busserolles, J.; Megías, J.; Terencio, M.C.; Alcaraz, M.J. Heme oxygenase-1 inhibits apoptosis in Caco-2 cells via activation of Akt pathway. Int. J. Biochem. Cell Biol., 2006, 38, 1510-7.
143. Vaquero, E.C.; Edderkaoui, M.; Pandol, S.J.; Gukovsky, I.; Gukovskaya, A.S. Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells. J. Biol. Chem., 2004, 279, 34643-54.
144. Ames, B.N. Endogenous DNA damage as related to cancer and aging. Mutat. Res., 1989, 214, 41-6.
145. Esterbauer, H.; Eckl, P.; Ortner, A. Possible mutagens derived from lipids and lipid precursors. Mutat. Res., 1990, 238, 223-33.
146. Marnett, L.J. Lipid peroxidation-DNA damage by malondialdehyde. Mutat. Res., 1999, 424, 83-95.
147. Hussain, S.P.; Harris, C.C. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res., 1998, 58, 4023-37.
148. Irani, K.; Xia, Y.; Zweier, J.L.; Sollott, S.J.; Der, C.J.; Fearon, E.R.; Sundaresan, M.; Finkel, T.; Goldschmidt-Clermont, P.J. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science, 1997, 275, 1649-52.
149. Brar, S.S.; Corbin, Z.; Kennedy, T.P.; Hemendinger, R.; Thornton, L.; Bommarius, B.; Arnold, R.S.; Whorton, A.R.; Sturrock, A.B.; Huecksteadt, T.P.; Quinn, M.T.; Krenitsky, K.; Ardie, K.G.; Lambeth, J.D.; Hoidal, J.R. NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells. Am. J. Physiol. Cell Physiol., 2003, 285, C353-69.
150. Lin, K.I.; Pasinelli, P.; Brown, R.H.; Hardwick, J.M.; Ratan, R.R. Decreased intracellular superoxide levels activate Sindbis virus-induced apoptosis. J. Biol. Chem., 1999, 274, 13650-5.
151. Lindahl, T. Instability and decay of the primary structure of DNA. Nature, 1993, 362, 709-15.
152. Slupphaug, G.; Kavli, B.; Krokan, H.E. The interacting pathways for prevention and repair of oxidative DNA damage. Mutat. Res., 2003, 531, 231-51.
153. Järvinen, R.; Knekt, P.; Hakulinen, T.; Rissanen, H.; Heliövaara, M. Dietary fat, cholesterol and colorectal cancer in a prospective study. Br. J. Cancer, 2001, 85, 357-61.
154. Lipkin, M.; Yang, K.; Edelmann, W.; Xue, L.; Fan, K.; Risio, M.; Newmark, H.; Kucherlapati, R. Preclinical mouse models for cancer chemoprevention studies. Ann. NY Acad. Sci., 1999, 889, 14-9.
155. Goldstein, J.L.; Brown, M.S. Regulation of the mevalonate pathway. Nature, 1990, 343, 425-30.
156. Wächtershüser, A.; Akoglu, B.; Stein, J. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis, 2001, 22, 1061-7.
157. Crisby, M. Modulation of the inflammatory process by statins. Drugs Today (Barc), 2003, 39, 137-43.
158. Bjerre, L.M.; LeLorier, J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am. J. Med., 2001, 110, 716-23.
159. Poynter, J.N.; Gruber, S.B.; Higgins, P.D.; Almog, R.; Bonner, J.D.; Rennert, H.S.; Low, M.; Greenson, J.K.; Rennert, G. Statins and the risk of colorectal cancer. N. Engl. J. Med., 2005, 352, 2184-92.
160. Blais, L.; Desgagné, A.; LeLorier, J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study. Arch. Intern. Med., 2000, 160, 2363-8.
161. Friis, S.; Poulsen, A.H.; Johnsen, S.P.; McLaughlin, J.K.; Fryzek, J.P.; Dalton, S.O.; Sørensen, H.T.; Olsen, J.H. Cancer risk among statin users: A population-based cohort study. Int. J. Cancer, 2005, 114, 643-7.
162. Graaf, M.R.; Beiderbeck, A.B.; Egberts, A.C.; Richel, D.J.; Guchelaar, H.J. The risk of cancer in users of statins. J. Clin. Oncol., 2004, 22, 2388-94.
163. Jacobs, E.J.; Rodriguez, C.; Brady, K.A.; Connell, C.J.; Thun, M.J.; Calle, E.E. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J. Natl. Cancer Inst., 2006, 98, 69-72.
164. Kaye, J.A.; Jick, H. Statin use and cancer risk in the General Practice Research Database. Br. J. Cancer, 2004, 90, 635-7.
165. Narisawa, T.; Fukaura, Y.; Terada, K.; Umezawa, A.; Tanida, N.; Yazawa, K.; Ishikawa, C. Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. Carcinogenesis, 1994, 15, 2045-8.
166. Narisawa, T.; Morotomi, M.; Fukaura, Y.; Hasebe, M.; Ito, M.; Aizawa, R. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn. J. Cancer Res., 1996, 87, 798-804.
167. Rao, C.V.; Newmark, H.L.; Reddy, B.S. Chemopreventive effect of farnesol and lanosterol on colon carcinogenesis. Cancer Detect. Prev., 2002, 26, 419-25.
168. Reddy, B.S.; Wang, C.X.; Kong, A.N.; Khor, T.O.; Zheng, X.; Steele, V.E.; Kopelovich, L.; Rao, C.V. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res., 2006, 66, 4542-6.
169. Yasui, Y.; Suzuki, R.; Miyamoto, S.; Tsukamoto, T.; Sugie, S.; Kohno, H.; Tanaka, T. A lipophilic statin, pitavastatin, suppresses inflammation-associated mouse colon carcinogenesis. Int. J. Cancer, 2007, 121, 2331-9.
170. Denoyelle, C.; Vasse, M.; Körner, M.; Mishal, Z.; Ganné, F.; Vannier, J.P.; Soria, J.; Soria, C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: An in vitro study. Carcinogenesis, 2001, 22, 1139-48.
171. Hirai, A.; Nakamura, S.; Noguchi, Y.; Yasuda, T.; Kitagawa, M.; Tatsuno, I.; Oeda, T.; Tahara, K.; Terano, T.; Narumiya, S.; Kohn, L.D.; Saito, Y. Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J. Biol. Chem., 1997, 272, 13-6.
172. Swamy, M.V.; Cooma, I.; Reddy, B.S.; Rao, C.V. Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: A novel approach in developing effective chemopreventive regimens. Int. J. Oncol., 2002, 20, 753-9.
173. Chawla, A.; Repa, J.J.; Evans, R.M.; Mangelsdorf, D.J. Nuclear receptors and lipid physiology: Opening the X-files. Science, 2001, 294, 1866-70.
174. Shulman, A.I.; Mangelsdorf, D.J. Retinoid x receptor heterodimers in the metabolic syndrome. N. Engl. J. Med., 2005, 353, 604-15.
175. Desreumaux, P.; Dubuquoy, L.; Nutten, S.; Peuchmaur, M.; Englaro, W.; Schoonjans, K.; Derijard, B.; Desvergne, B.; Wahli, W.; Chambon, P.; Leibowitz, M.D.; Colombel, J.F.; Auwerx, J. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/ peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J. Exp. Med., 2001, 193, 827-38.
176. Xiao, J.H.; Ghosn, C.; Hinchman, C.; Forbes, C.; Wang, J.; Snider, N.; Cordrey, A.; Zhao, Y.; Chandraratna, R.A. Adenomatous polyposis coli (APC)-independent regulation of beta-catenin degradation via a retinoid X receptor-mediated pathway. J. Biol. Chem., 2003, 278, 29954-62.
177. Mangelsdorf, D.J.; Evans, R.M. The RXR heterodimers and orphan receptors. Cell, 1995, 83, 841-50.
178. Heyman, R.A.; Mangelsdorf, D.J.; Dyck, J.A.; Stein, R.B.; Eichele, G.; Evans, R.M.; Thaller, C. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell, 1992, 68, 397-406.
179. Mukherjee, R.; Davies, P.J.; Crombie, D.L.; Bischoff, E.D.; Cesario, R.M.; Jow, L.; Hamann, L.G.; Boehm, M.F.; Mondon, C.E.; Nadzan, A.M.; Paterniti, J.R.J.; Heyman, R.A. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature, 1997, 386, 407-10.
180. Wu, K.; Kim, H.T.; Rodriquez, J.L.; Hilsenbeck, S.G.; Mohsin, S.K.; Xu, X.C.; Lamph, W.W.; Kuhn, J.G.; Green, J.E.; Brown, P.H. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol. Biomarkers Prev., 2002, 11, 467-74.
181. Vuligonda, V.; Thacher, S.M.; Chandraratna, R.A. Enantioselective syntheses of potent retinoid X receptor ligands: Differential biological activities of individual antipodes. J. Med. Chem., 2001, 44, 2298-303.
182. Janakiram, N.B.; Cooma, I.; Mohammed, A.; Steele, V.E.; Rao, C.V. Beta-ionone inhibits colonic aberrant crypt foci formation in rats, suppresses cell growth, and induces retinoid X receptor-alpha in human colon cancer cells. Mol. Cancer Ther., 2008, 7, 181-90.
183. Deroo, B.J.; Korach, K.S. Estrogen receptors and human disease. J. Clin. Invest., 2006, 116, 561-70.
184. Levin, E.R. Integration of the extranuclear and nuclear actions of estrogen. Mol. Endocrinol., 2005, 19, 1951-9
185. Kennelly, R.; Kavanagh, D.O.; Hogan, A.M.; Winter, D.C. Oestrogen and the colon: Potential mechanisms for cancer prevention. Lancet Oncol., 2008, 9, 385-91.
186. Newcomb, P.A.; Storer, B.E. Postmenopausal hormone use and risk of large-bowel cancer. J. Natl. Cancer Inst., 1995, 87, 1067-71.
187. Singh, S.; Langman, M.J. Oestrogen and colonic epithelial cell growth. Gut, 1995, 37, 737-9.
188. Fernandez, E.; La Vecchia, C.; Braga, C.; Talamini, R.; Negri, E.; Parazzini, F.; Franceschi, S. Hormone replacement therapy and risk of colon and rectal cancer. Cancer Epidemiol. Biomarkers Prev., 1998, 7, 329-33.
189. Troisi, R.; Schairer, C.; Chow, W.H.; Schatzkin, A.; Brinton, L.A.; Fraumeni, J.F.J. A prospective study of menopausal hormones and risk of colorectal cancer (United States). Cancer Causes Control, 1997, 8, 130-8.
190. No author listed. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet, 1997, 350, 1047-59.
191. Koehler, K.F.; Helguero, L.A.; Haldosén, L.A.; Warner, M.; Gustafsson, J.A. Reflections on the discovery and significance of estrogen receptor beta. Endocr. Rev., 2005, 26, 465-78.
192. Konstantinopoulos, P.A.; Kominea, A.; Vandoros, G.; Sykiotis, G.P.; Andricopoulos, P.; Varakis, I.; Sotiropoulou-Bonikou, G.; Papavassiliou, A.G. Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur. J. Cancer, 2003, 39, 1251-8.
193. Narayan, S.; Rajakumar, G.; Prouix, H.; Singh, P. Estradiol is trophic for colon cancer in mice: Effect on ornithine decarboxylase and c-myc messenger RNA. Gastroenterology, 1992, 103, 1823-32.
194. Katzenellenbogen, B.S.; Choi, I.; Delage-Mourroux, R.; Ediger, T.R.; Martini, P.G.; Montano, M.; Sun, J.; Weis, K.; Katzenellenbogen, J.A. Molecular mechanisms of estrogen action: Selective ligands and receptor pharmacology. J. Steroid. Biochem. Mol. Biol., 2000, 74, 279-85.
195. Katzenellenbogen, B.S.; Montano, M.M.; Ediger, T.R.; Sun, J.; Ekena, K.; Lazennec, G.; Martini, P.G.; McInerney, E.M.; Delage-Mourroux, R.; Weis, K.; Katzenellenbogen, J.A. Estrogen receptors: Selective ligands, partners, and distinctive pharmacology. Recent Prog. Horm. Res., 2000, 55, 163-93.
196. Di Leo, A.; Messa, C.; Russo, F.; Misciagna, G.; Guerra, V.; Taveri, R.; Leo, S. Prognostic value of cytosolic estrogen receptors in human colorectal carcinoma and surrounding mucosa. Preliminary results. Dig. Dis. Sci., 1994, 39, 2038-42.
197. Campbell-Thompson, M.; Lynch, I.J.; Bhardwaj, B. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res., 2001, 61, 632-40.
198. Cho, N.L.; Javid, S.H.; Carothers, A.M.; Redston, M.; Bertagnolli, M.M. Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice. Cancer Res., 2007, 67, 2366-72.
199. Foley, E.F.; Jazaer, i.A.A.; Shupnik, M.A.; Jazaeri, O.; Rice, L.W. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res., 2000, 60, 245-8.
200. Xie, L.Q.; Yu, J.P.; Luo, H.S. Expression of estrogen receptor beta in human colorectal cancer. World J. Gastroenterol., 2004, 10, 214-7.
201. Wada-Hiraike, O.; Imamov, O.; Hiraike, H.; Hultenby, K.; Schwend, T.; Omoto, Y.; Warner, M.; Gustafsson, J.A. Role of estrogen receptor beta in colonic epithelium. Proc. Natl. Acad. Sci. USA, 2006, 103, 2959-64.
202. Kansra, S.; Yamagata, S.; Sneade, L.; Foster, L.; Ben-Jonathan, N. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol.Cell Endocrinol., 2005, 239, 27-36.
203. Kuruppu, D.; Christophi, C.; Bertram, J.F.; O'Brien, P.E. Tamoxifen inhibits colorectal cancer metastases in the liver: A study in a murine model. J. Gastroenterol. Hepatol., 1998, 13, 521-7.
204. Cook, L.S.; Weiss, N.S.; Pharris-Ciurej, N.; Schwartz, S.M.; White, E. Colorectal cancer following tamoxifen therapy for breast cancer (United States). Cancer Causes Control, 2001, 12, 405-10.
205. Grodstein, F.; Newcomb, P.A.; Stampfer, M.J. Postmenopausal hormone therapy and the risk of colorectal cancer: A review and meta-analysis. Am. J. Med., 1999, 106, 574-82.
206. Vogel, V.G.; Costantino, J.P.; Wickerham, D.L.; Cronin, W.M.; Cecchini, R.S.; Atkins, J.N.; Bevers, T.B.; Fehrenbacher, L.; Pajon, E.R.J.; Wade, J.L.r.; Robidoux, A.; Margolese, R.G.; James, J.; Lippman, S.M.; Runowicz, C.D.; Ganz, P.A.; Reis, S.E.; McCaskill-Stevens, W.; Ford, L.G.; Jordan, V.C.; Wolmark, N. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 2006, 295, 2727-41.
207. Ettinger, B.; Black, D.M.; Mitlak, B.H.; Knickerbocker, R.K.; Nickelsen, T.; Genant, H.K.; Christiansen, C.; Delmas, P.D.; Zanchetta, J.R.; Stakkestad, J.; Glüer, C.C.; Krueger, K.; Cohen, F.J.; Eckert, S.; Ensrud, K.E.; Avioli, L.V.; Lips, P.; Cummings, S.R. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA, 1999, 282, 637-45.
208. Picariello, L.; Fiorelli, G.; Martineti, V.; Tognarini, I.; Pampaloni, B.; Tonelli, F.; Brandi, M.L. Growth response of colon cancer cell lines to selective estrogen receptor modulators. Anticancer Res., 2003, 23, 2419-24.
209. Slattery, M.L.; Sweeney, C.; Murtaugh, M.; Ma, K.N.; Wolff, R.K.; Potter, J.D.; Caan, B.J.; Samowitz, W. Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. Cancer Epidemiol. Biomarkers Prev., 2005, 14, 2936-42.
210. Huelsken, J.; Birchmeier, W. New aspects of Wnt signaling pathways in higher vertebrates. Curr. Opin. Genet. Dev., 2001, 11, 547-53.
211. Lee, H.K.; Choi, Y.S.; Park, Y.A.; Jeong, S. Modulation of oncogenic transcription and alternative splicing by beta-catenin and an RNA aptamer in colon cancer cells. Cancer Res., 2006, 66, 10560-6.
212. Mulholland, D.J.; Dedhar, S.; Coetzee, G.A.; Nelson, C.C. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr. Rev., 2005, 26, 898-915.
213. Kouzmenko, A.P.; Takeyama, K.; Ito, S.; Furutani, T.; Sawatsubashi, S.; Maki, A.; Suzuki, E.; Kawasaki, Y.; Akiyama, T.; Tabata, T.; Kato, S. Wnt/beta-catenin and estrogen signaling converge in vivo. J. Biol. Chem., 2004, 279, 40255-8.
214. Powell, S.M.; Zilz, N.; Beazer-Barclay, Y.; Bryan, T.M.; Hamilton, S.R.; Thibodeau, S.N.; Vogelstein, B.; Kinzler, K.W. APC mutations occur early during colorectal tumorigenesis. Nature, 1992, 359, 235-7.
215. Behrens, J.; Jerchow, B.A.; Würtele, M.; Grimm, J.; Asbrand, C.; Wirtz, R.; Kühl, M.; Wedlich, D.; Birchmeier, W. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science, 1998, 280, 596-9.
216. Rubinfeld, B.; Albert, I.; Porfiri, E.; Fiol, C.; Munemitsu, S.; Polakis, P. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science, 1996, 272, 1023-6.
217. Sparks, A.B.; Morin, P.J.; Vogelstein, B.; Kinzler, K.W. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res., 1998, 58, 1130-4.
218. Behrens, J.; von Kries, J.P.; Kühl, M.; Bruhn, L.; Wedlich, D.; Grosschedl, R.; Birchmeier, W. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature, 1996, 382, 638-42.
219. Korinek, V.; Barker, N.; Morin, P.J.; van Wichen, D.; de Weger, R.; Kinzler, K.W.; Vogelstein, B.; Clevers, H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/-colon carcinoma. Science, 1997, 275, 1784-7.
220. Morin, P.J.; Sparks, A.B.; Korinek, V.; Barker, N.; Clevers, H.; Vogelstein, B.; Kinzler, K.W. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science, 1997, 275, 1787-90.
221. Oyama, T.; Yamada, Y.; Hata, K.; Tomita, H.; Hirata, A.; Sheng, H.; Hara, A.; Aoki, H.; Kunisada, T.; Yamashita, S.; Mori, H. Further upregulation of beta-catenin/Tcf transcription is involved in the development of macroscopic tumors in the colon of ApcMin/+ mice. Carcinogenesis, 2008, 29, 666-72.
222. de Vogel, S.; van Engeland, M.; Lüchtenborg, M.; de Bruïne, A.P.; Roemen, G.M.; Lentjes, M.H.; Goldbohm, R.A.; van den Brandt, P.A.; de Goeij, A.F.; Weijenberg, M.P. Dietary folate and APC mutations in sporadic colorectal cancer. J. Nutr., 2006, 136, 3015-21.
223. Cole, B.F.; Baron, J.A.; Sandler, R.S.; Haile, R.W.; Ahnen, D.J.; Bresalier, R.S.; McKeown-Eyssen, G.; Summers, R.W.; Rothstein, R.I.; Burke, C.A.; Snover, D.C.; Church, T.R.; Allen, J.I.; Robertson, D.J.; Beck, G.J.; Bond, J.H.; Byers, T.; Mandel, J.S.; Mott, L.A.; Pearson, L.H.; Barry, E.L.; Rees, J.R.; Marcon, N.; Saibil, F.; Ueland, P.; Greenberg, E.R. Polyp Prevention Study Group. Folic acid for the prevention of colorectal adenomas: A randomized clinical trial. JAMA, 2007, 297, 2351-9.
224. Nath, N.; Kashfi, K.; Chen, J.; Rigas, B. Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association. Proc. Natl. Acad. Sci. USA, 2003, 100, 12584-9.
225. Dean, N.M.; Bennett, C.F. Antisense oligonucleotide-based therapeutics for cancer. Oncogene, 2003, 22, 9087-96.
226. Luu, H.H.; Zhang, R.; Haydon, R.C.; Rayburn, E.; Kang, Q.; Si, W.; Park, J.K.; Wang, H.; Peng, Y.; Jiang, W.; He, T.C. Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr. Cancer Drug Targets, 2004, 4, 653-71.
227. Dihlmann, S.; von Knebel Doeberitz, M. Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int. J. Cancer, 2005, 113, 515-24.
228. Lepourcelet, M.; Chen, Y.N.; France, D.S.; Wang, H.; Crews, P.; Petersen, F.; Bruseo, C.; Wood, A.W.; Shivdasani, R.A. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell, 2004, 5, 91-102.
229. Kiselyov, A.S.; Tkachenko, S.E.; Balakin, K.V.; Ivachtchenko, A.V. Small-molecule modulators of Hh and Wnt signaling pathways. Expert Opin. Ther. Targets, 2007, 11, 1087-101.
230. Frank, D.A. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett., 2007, 251, 199-210.
231. Ng, D.C.; Lin, B.H.; Lim, C.P.; Huang, G.; Zhang, T.; Poli, V.; Cao, X. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J. Cell Biol., 2006, 172, 245-57.
232. Kim, D.J.; K.S., C.; Sano, S.; Digiovanni, J. Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. Mol. Carcinog., 2007, 46, 725-31.
233. Ma, X.T.; Wang, S.; Ye, Y.J.; Du, R.Y.; Cui, Z.R.; Somsouk, M. Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. World J. Gastroenterol., 2004, 10, 1569-73.
234. Tsareva, S.A.; Moriggl, R.; Corvinus, F.M.; Wiederanders, B.; Schütz, A.; Kovacic, B.; Friedrich, K. Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. Neoplasia, 2007, 9, 279-91.
235. Turkson, J. STAT proteins as novel targets for cancer drug discovery. Expert Opin. Ther. Targets, 2004, 8, 409-22.
236. Gao, S.P.; Bromberg, J.F. Touched and moved by STAT3. Sci. STKE, 2006, 343, pe30.
237. Leslie, K.; Lang, C.; Devgan, G.; Azare, J.; Berishaj, M.; Gerald, W.; Kim, Y.B.; Paz, K.; Darnell, J.E.; Albanese, C.; Sakamaki, T.; Pestell, R.; Bromberg, J. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res., 2006, 66, 2544-52.
238. Chen, Z.; Han, Z.C. STAT3: A critical transcription activator in angiogenesis. Med. Res. Rev., 2008, 28, 185-200.
239. Klampfer, L. The role of signal transducers and activators of transcription in colon cancer. Front Biosci., 2008, 13, 2888-99.
240. Germain, D.; Frank, D.A. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin. Cancer Res., 2007, 13, 5665-9.
241. Alvarez-Garcia, I.; Miska, E.A. MicroRNA functions in animal development and human disease. Development, 2005, 132, 4653-62.
242. Farh, K.K.; Grimson, A.; Jan, C.; Lewis, B.P.; Johnston, W.K.; Lim, L.P.; Burge, C.B.; Bartel, D.P. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science, 2005, 310, 1817-21.
243. Krek, A.; Grün, D.; Poy, M.N.; Wolf, R.; Rosenberg, L.; Epstein, E.J.; MacMenamin, P.; da Piedade, I.; Gunsalus, K.C.; Stoffel, M.; Rajewsky, N. Combinatorial microRNA target predictions. Nat. Genet., 2005, 37, 495-500.
244. Mazière, P.; Enright, A.J. Prediction of microRNA targets. Drug Discov. Today, 2007, 12, 452-8.
245. Bandrés, E.; Cubedo, E.; Agirre, X.; Malumbres, R.; Zárate, R.; Ramirez, N.; Abajo, A.; Navarro, A.; Moreno, I.; Monzó, M.; García-Foncillas, J. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol. Cancer, 2006, 5, 29.
246. Cummins, J.M.; He, Y.; Leary, R.J.; Pagliarini, R.; Diaz, L.A.J.; Sjoblom, T.; Barad, O.; Bentwich, Z.; Szafranska, A.E.; Labourier, E.; Raymond, C.K.; Roberts, B.S.; Juhl, H.; Kinzler, K.W.; Vogelstein, B.; Velculescu, V.E. The colorectal microRNAome. Proc. Natl. Acad. Sci. USA, 2006, 103, 3687-92.
247. Hayashita, Y.; Osada, H.; Tatematsu, Y.; Yamada, H.; Yanagisawa, K.; Tomida, S.; Yatabe, Y.; Kawahara, K.; Sekido, Y.; Takahashi, T. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res., 2005, 65, 9628-32.
248. Calin, G.A.; Croce, C.M. MicroRNA-cancer connection: The beginning of a new tale. Cancer Res., 2006, 66, 7390-4.
249. Calin, G.A.; Croce, C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer, 2006, 6, 857-66.
250. Chang, T.C.; Wentzel, E.A.; Kent, O.A.; Ramachandran, K.; Mullendore, M.; Lee, K.H.; Feldmann, G.; Yamakuchi, M.; Ferlito, M.; Lowenstein, C.J.; Arking, D.E.; Beer, M.A.; Maitra, A.; Mendell, J.T. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell, 2007, 26, 745-52.
251. Michael, M.Z.; O'Connor, S.M.; van Holst Pellekaan, N.G.; Young, G.P.; James, R.J. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol. Cancer Res., 2003, 1, 882-91.
252. Akao, Y.; Nakagawa, Y.; Naoe, T. MicroRNA-143 and -145 in colon cancer. DNA Cell Biol., 2007, 26, 311-20.
253. Tazawa, H.; Tsuchiya, N.; Izumiya, M.; Nakagama, H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc. Natl. Acad. Sci. USA, 2007, 104, 15472-7.
254. Brummelkamp, T.R.; Bernards, R.; Agami, R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell, 2002, 2, 243-7.
255. Lv, W.; Zhang, C.; Hao, J. RNAi technology: A revolutionary tool for the colorectal cancer therapeutics. World J. Gastroenterol., 2006, 12, 4636-9.
256. Fan, Y.; Zhang, Y.L.; Wu, Y.; Zhang, W.; Wang, Y.H.; Cheng, Z.M.; Li, H. Inhibition of signal transducer and activator of transcription 3 expression by RNA interference suppresses invasion through inducing anoikis in human colon cancer cells. World J. Gastroenterol., 2008, 14, 428-34.
257. Charames, G.S.; Bapat, B. Cyclooxygenase-2 knockdown by RNA interference in colon cancer. Int. J. Oncol., 2006, 28, 543-9.
258. Jiang, M.; Milner, J. Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Dev., 2003, 17, 832-7.
259. Yang, M.; Zhong, W.W.; Srivastava, N.; Slavin, A.; Yang, J.; Hoey, T.; An, S. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. Proc. Natl. Acad. Sci. USA, 2005, 102, 6027-32.
260. Aravin, A.A.; Hannon, G.J.; Brennecke, J. The Piwi-piRNA pathway provides an adaptive defense in the transposon arms race. Science, 2007, 318, 761-4.
261. Klattenhoff, C.; Theurkauf, W. Biogenesis and germline functions of piRNAs. Development, 2008, 135, 3-9.
262. O'Donnell, K.A.; Boeke, J.D. Mighty Piwis defend the germline against genome intruders. Cell, 2007, 129, 37-44.
263. Qiao, D.; Zeeman, A.M.; Deng, W.; Looijenga, L.H.; Lin, H. Molecular characterization of hiwi, a human member of the piwi gene family whose overexpression is correlated to seminomas. Oncogene, 2002, 21, 3988-99.
264. Liu, X.; Sun, Y.; Guo, J.; Ma, H.; Li, J.; Dong, B.; Jin, G.; Zhang, J.; Wu, J.; Meng, L.; Shou, C. Expression of hiwi gene in human gastric cancer was associated with proliferation of cancer cells. Int. J. Cancer, 2006, 118, 1922-9.